No 6 (2011)

The article discuss the problem of anejaculation, which represent the absence of antegrade ejaculation during normal sexual intercourse or any other form of sexual activity. Data for the etiology and pathogenesis of this disease according to cause of violation of ejaculation, and diagnosis, classification and treatment principles are presented. Taking into account the fact that results of treatment of patients with anejaculation remain generally unsatisfactory despite the use of various modern therapies, particular attention should be given to prevention of disease.

The article discusses various methods of treatment of nausea and vomiting in pregnancy (non-pharmacological and pharmacological). Among the pharmacological methods, including for self-treatment, plant preparation (ginger, peppermint and raspberry leaves) are widespread. Medications used for treatment of these symptoms in pregnant women include pyridoxine, H1-blockers, dopamine and serotonin receptors antagonists, and glucocorticoids. However, despite the large selection of antiemetics, evidence-based data for their safety and efficacy in pregnant women are limited. Further studies on the effectiveness and safety of drugs used for the treatment of nausea and vomiting in pregnant women are necessary.

Due to the growing antibiotic resistance of microorganisms and emerging challenges in the adequate selection of antimicrobial drugs on this background, bacteriophages have good prospects as an antimicrobial therapy. The article presents the historical data concerning the discovery and development of bacteriophages; their mechanism of action, classification, application, release forms and basic preparations of bacteriophages used in Russia are described. A distinctive feature of bacteriophages as therapeutic agents is an almost complete lack of side effects that allow its administration for patients of different age groups without any restrictions and application of polyvalent bacteriophages in the absence of results of bacteriological tests.

The article presents the data for the common infection of the womans genital tract - vulvovaginal candidiasis (etiology, risk factors, route of infection, diagnosis and treatment). Butokonazole nitrate (Ginofort) in the form of cream for intravaginal use is recommended as the drug of choice for the treatment of uncomplicated vulvovaginal candidiasis.

The article presents the results of study based on observation of 50 women aged 25-45 years with adenomyosis complicated by pelvic pain syndrome. Patients received drugs Indinol and Epigallat, 2 capsules of each drug 2 times a day within 9 months. After treatment, decrease of abdominal pain was observed in 74% of women, and improvement of menstrual function in 92%. According to the instrumental control (pelvic ultrasound examination), reduction of heterotopic foci of adenomyosis and decrease of their vascularization was noted in 60% of patients. It is found that the antiproliferative effect of the drugs allowed to arrest pain symptoms of adenomyosis, resume or improve sex life and improve the quality of life for these women.

Increased number of relatively young men who underwent brachytherapy for localized prostate cancer has led to increase the relevance of the question of quality of life for these patients. Erectile dysfunction (ED) is one of the major factors adversely affecting the quality of life. The high prevalence of ED after brachytherapy and the lack of a unified approach to safe and effective therapy for this condition dictate the need for more in-depth study of the problem, which is extremely important from the standpoint of optimizing the treatment of this category of patients.

The article considers the results of study included 85 men with premature ejaculation (PE) and concomitant erectile dysfunction (ED), whose goal was optimization of treatment with phosphodiesterase type 5 (PDE-5) inhibitor - tadalafil. The results have shown that the use of PDE-5 inhibitors in clinical practice enhances the treatment of patients with PE in combination with ED or without ED. Given the pharmacokinetic characteristics of tadalafil, this drug may be considered as the most appropriate PDE-5 inhibitor for the treatment of patients with PE.